Holistic solutions every step of the way,
from medical and pharmaceutical device development to
regenerative medicine support.
NEWS RELEASE
-
2024.04.12
EPS' viewpoint was published in MedTech Outlook APAC.
-
2024.04.01
Service brochures are available
-
2024.03.21
EPNextS Group will collaborate with Frontage Laboratories, Inc. for Early Phase Clinical Trial and Clinical Site Management in the United States to Improve “Drug Lag” and “Drug Loss” Issues in Japan.
-
2024.01.16
EPS Corporation was awarded as one of the Top 10 Companies of “Regenerative Medicine Solutions Providers in APAC 2024”
-
2023.10.19
Notice of Executive Structure
-
2023.09.13
EPS Corporation was selected as a finalist in the “Best CRO/CDMO” category of the “Citeline Pharma Intelligence Awards Japan 2023”.
-
2023.09.13
Our employee YAMAMOTO Mayumi will speak at DIA Asia
-
2023.09.01
EPS will be exhibiting at the Outsourcing In Clinical Trials Southern California 2023 in San Diego, CA
-
2023.07.06
EPS Supported Important Japan-led International Investigator-Initiated HR+/HER2- Breast Cancer Study in Asia Pacific
-
2023.05.01
EPS will be exhibiting at the 2023 DIA Annual Meeting in Boston, MA
-
2023.04.28
【Webinar LIVE】Clinical information in Korea(Regurlatory Affairs and Clinical Trials in Korea)
-
2023.04.13
EPS Group supports Citeline Pharma Intelligence Awards Japan 2023 as a sponsor!
-
2023.03.30
Service brochures are available
-
2023.03.01
Notice Regarding Investment of EPS Corporation in Helte Co., Ltd.
-
2023.02.13
EPS will support administrative side of MHLW’s efforts to promote PHRs and enhance the health of Japanese citizens
-
2022.12.12
PharmaSUG Single Day Event
-
2022.09.09
EPS will be exhibiting at the 2022 DIA CHINA Annual Meeting in Suzhou(Jump to our website for customers outside of Japan)
-
2022.07.04
EPS Group Form Strategic Reorganization for CRO Business
-
2022.02.17
Announcement on Reorganization of CRO Business